B. Riley initiates coverage of Adamas Trust (ADAM) with a Buy rating and a $9 price target, citing the REIT's strategic portfolio pivot towards higher-quality Agency RMBS as a key driver for potential revaluation.
Barclays has initiated coverage on Bloom Energy (NYSE: BE) with an 'Equal Weight' rating and a $153 price target, citing strong fundamentals but suggesting the market has already priced in its near-term growth trajectory, particularly from AI data center demand.
Despite a cautious 'Moderate Sell' consensus, Paramount Skydance (PSKY) carries an average price target of $14.08, implying significant potential upside. The media giant's recent Q3 2025 results highlighted robust Paramount+ subscriber growth, even as investors weigh heavy content investments and integration risks.
Wall Street firms have issued a series of bullish upgrades for Karman Holdings Inc. (KRMN), significantly raising revenue projections and price targets for the specialty materials company as growth expectations accelerate.
Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Janus Henderson Group (NYSE:JHG) finds itself at the center of a valuation debate. While some models peg the asset manager as modestly undervalued, a deeper cash flow analysis suggests a starkly different picture, leaving investors to weigh competing narratives amid industry headwinds.
Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
Mizuho Securities dramatically raised its price target on SanDisk, forecasting a severe NAND flash memory shortage driven by explosive AI server demand and constrained production capacity through 2027.
Shares of Brookdale Senior Living (BKD) rallied sharply, reaching their highest level since 2016, fueled by a significant price target increase from RBC Capital and optimistic preliminary earnings guidance for 2025.
Shares of gaming and hospitality REIT VICI Properties have faced recent headwinds, trading near $28 and presenting a significant discount to analyst targets. We examine whether the current valuation gap signals a buying opportunity or reflects deeper sectoral risks.
Shoppers are bracing for another wave of price increases as new import taxes take effect, targeting a range of everyday items from spirits to seafood. Experts warn the hikes will squeeze household budgets and force tough choices at the supermarket.
A sharp supply crunch is driving contract prices for mainstream DRAM memory chips up by as much as 95% quarter-on-quarter in early 2025, according to a revised forecast from market analyst TrendForce.
Despite a sharp decline in its share price to a 52-week low, DocuSign finds analyst support holding firm as it launches new AI-enhanced tools. The market appears to be reassessing the e-signature leader's growth trajectory against a backdrop of rising competition and macroeconomic pressures.
As cocoa futures pull back from historic highs, Morgan Stanley boosts its price target for snack giant Mondelez International, citing improved earnings visibility. The firm maintains an Overweight rating, highlighting the company's resilient financials and shareholder returns amidst lingering sales growth uncertainties.
